Literature DB >> 34344926

Comprehensive analysis of the expression and prognosis for TNFAIPs in head and neck cancer.

Gaochen Lan1, Xiaoling Yu1, Xin Sun2, Wan Li1, Yanna Zhao1, Jinjian Lan1, Xiaolong Wu1, Ruilan Gao3.   

Abstract

Head and neck cancer (HNC) tumorigenesis involves a combination of multiple genetic alteration processes. Tumour necrosis factor-alpha-induced proteins (TNFAIPs) are involved in tumour development and progression, but few studies have been conducted on these factors in HNC. We aimed to analyse TNFAIPs and assess their potential as prognostic biomarkers and therapeutic targets using the Oncomine, UALCAN, Human Protein Atlas, LinkedOmics, cBioPortal, GeneMANIA, Enrichr, and Tumor IMmune Estimation Resource databases. We found that the transcript levels of TNFAIP1, TNFAIP3, EFNA1, TNFAIP6 and TNFAIP8 were increased, while those of TNFAIP8L3 and STEAP4 were reduced in HNC tissues versus normal tissues. The EFNA1, TNFAIP8 and TNFAIP8L3 expression levels were significantly correlated with the pathological stage. In HNC patients, high PTX3 and TNFAIP6 transcript levels were significantly associated with shorter overall survival (OS). Moreover, genetic alterations in TNFAIP1, TNFAIP6, and STEAP4 resulted in poorer disease-free survival, progression-free survival, and OS, respectively. TNFAIPs may mediate HNC tumorigenesis by regulating PI3K-Akt, Ras and other signalling pathways. TNFAIPs are also closely correlated with the infiltration of immune cells, including B cells, CD8+ T cells, CD4+ T cells, etc. The data above indicate that TNFAIPs may be potential biomarkers and therapeutic targets for HNC.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34344926     DOI: 10.1038/s41598-021-95160-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  48 in total

1.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

Review 2.  Head and Neck Cancer.

Authors:  Laura Q M Chow
Journal:  N Engl J Med       Date:  2020-01-02       Impact factor: 91.245

3.  [Use of the immunofluorescence method for the differential diagnosis of measles and rashes of unknown etiology].

Authors:  I Ia Eliseeva; L A Ivanova; S A Azarova; S A Demidova
Journal:  Vopr Virusol       Date:  1983 Jul-Aug

4.  TNFAIP3 inhibits migration and invasion in nasopharyngeal carcinoma by suppressing epithelial mesenchymal transition.

Authors:  T Huang; L Yin; J Wu; J J Gu; K Ding; N Zhang; M Y Du; L X Qian; Z W Lu; X He
Journal:  Neoplasma       Date:  2017       Impact factor: 2.575

Review 5.  Role of EFNA1 in tumorigenesis and prospects for cancer therapy.

Authors:  Yongping Hao; Guang Li
Journal:  Biomed Pharmacother       Date:  2020-07-31       Impact factor: 6.529

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.

Authors:  Erin Larkins; Gideon M Blumenthal; Weishi Yuan; Kun He; Rajeshwari Sridhara; Sriram Subramaniam; Hong Zhao; Chao Liu; Jingyu Yu; Kirsten B Goldberg; Amy E McKee; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2017-05-22

Review 9.  Tumor Necrosis Factor-α Induced Protein 8: Pathophysiology, Clinical Significance, and Regulatory Mechanism.

Authors:  Lei Zhang; Ran Liu; Ying-Yi Luan; Yong-Ming Yao
Journal:  Int J Biol Sci       Date:  2018-03-10       Impact factor: 6.580

10.  Comprehensive Analysis of the Expression and Prognosis for GBPs in Head and neck squamous cell carcinoma.

Authors:  Zeng-Hong Wu; Fucheng Cai; Yi Zhong
Journal:  Sci Rep       Date:  2020-04-08       Impact factor: 4.379

View more
  2 in total

1.  Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.

Authors:  Paola Vacca; Ignazio Caruana; Nicola Tumino; Gerrit Weber; Francesca Besi; Francesca Del Bufalo; Valentina Bertaina; Paola Paci; Linda Quatrini; Laura Antonucci; Matilde Sinibaldi; Concetta Quintarelli; Enrico Maggi; Biagio De Angelis; Franco Locatelli; Lorenzo Moretta
Journal:  J Hematol Oncol       Date:  2021-11-12       Impact factor: 17.388

2.  TNFAIP6 Promotes Gastric Carcinoma Cell Invasion via Upregulating PTX3 and Activating the Wnt/β-Catenin Signaling Pathway.

Authors:  Hongquan Cui; Ling Zhang; Bin Chen; Fengchun Zhang; Haiyan Xu; Guixiang Ma; Longnv Cao; Miao Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-07-06       Impact factor: 3.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.